Last edition
News about "Ulcerative Colitis treatment"
Biocon Expands Yesintek Biosimilar Market Access Globally
Biocon has secured market entry for Yesintek, its proposed Stelara biosimilar, in additional global markets, building on existing agreements with Janssen.
Ulcerative Colitis Treatment | 26/10/2026 | By News Bureau | 112
Merck's Tulisokibart Met Primary and Key Secondary Endpoints in Phase 3 ATLAS-UC Induction
Merck’s tulisokibart achieved both primary and key secondary endpoints in the phase 3 ATLAS-UC induction study, demonstrating significant efficacy in patients with moderately to severely active Ulcerative Colitis (UC).
Ulcerative Colitis Treatment | 23/06/2026 | By News Bureau | 508
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy